TWI646971B - 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用 - Google Patents

阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用 Download PDF

Info

Publication number
TWI646971B
TWI646971B TW104140659A TW104140659A TWI646971B TW I646971 B TWI646971 B TW I646971B TW 104140659 A TW104140659 A TW 104140659A TW 104140659 A TW104140659 A TW 104140659A TW I646971 B TWI646971 B TW I646971B
Authority
TW
Taiwan
Prior art keywords
prescription
patient
drip
drug
vitamin
Prior art date
Application number
TW104140659A
Other languages
English (en)
Other versions
TW201720457A (zh
Inventor
鄭恩哲
Original Assignee
鄭恩哲
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鄭恩哲 filed Critical 鄭恩哲
Priority to TW104140659A priority Critical patent/TWI646971B/zh
Priority to US15/000,093 priority patent/US10004781B2/en
Publication of TW201720457A publication Critical patent/TW201720457A/zh
Application granted granted Critical
Publication of TWI646971B publication Critical patent/TWI646971B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)

Abstract

一種阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用，其中該點 滴處方係包含有活血素、諾多必、喜美胃錠、解痙靈、安克疼、維他命B群、維他命B1、維他命C、克多羅多克、克勞酸、補斯可伴等成分所組成，該處方以活化病患肝臟及體內循環系統，來達到阻斷毒品中毒。該毒品阻斷應用係藉於急性戒斷部分經由注射該點滴處方及依臨床症狀控管投藥時機及安全用藥劑量，並加入適量哈泊度等輔助藥劑，藉此以解毒、緩解症狀、抑制躁動、清醒等程序，迅速成功阻斷急性戒斷毒癮者之急性戒斷症狀。

Description

阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
本發明係關於一種阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及應用，尤指一種經由點滴處方的注射及應用，以活化病患肝臟及體內循環系統，同時透過醫師及護士控管投藥時機及安全用藥劑量，以解毒、緩解症狀、抑制躁動、清醒等程序迅速成功阻斷急性戒斷毒癮者之急性戒斷症狀。
按，在醫學上，海洛英及嗎啡可作為強效鎮痛藥物，可用於心臟病、外傷、手術後的鎮痛，因具有強烈的成癮性，也被人作為強效毒品。使用初時感覺愉快安靜，無法集中精神，會產生夢幻現象。吸食後的12小時，身體由於得不到麻醉劑而無法正常運作，出現緊張、無法入睡、出汗、腸胃不適、四肢疼痛及痙攣等斷癮症狀，斷癮症狀將持續三到五天，吸食海洛英/嗎啡越久，斷癮症狀越長。過量吸食海洛英/嗎啡將造成急性中毒，其症狀包括昏睡、呼吸抑制、低血壓、瞳孔變小。使用海洛英/嗎啡後將產生高度心理及生理依賴性，上癮的人因身體對它有適應性，必須不斷增加吸食份量以得到相同效果，若長期吸食後，停止吸食會發生渴求藥物、不安、流淚、流汗、流鼻水、易怒、發抖、惡寒、打冷顫、厭食、腹瀉、身體捲曲、抽筋等禁斷症，所以成癮後極難戒治。傳統戒毒方法係透過鎮定劑、抗憂鬱藥物等，很難阻斷吸毒行為。
本發明人有鑑於使用海洛因或嗎啡成癮後難以戒斷，遂進行研究改善，期望幫助病人成功阻斷海洛因或嗎啡毒品。
爰是，本發明之目的係在提供一種用於阻斷海洛因或嗎啡毒癮的點滴處方。
為達成上述目的，本發明用於阻斷海洛因或嗎啡毒癮的點滴處方係包含下列藥名成分：一活血素、一諾多必、一喜美胃錠、一解痙靈、一安克疼、一維他命B群、一維他命B1、一維他命C、一克多羅多克、一克勞酸、一補斯可伴。其中，該活血素占3~13%的藥劑量；該諾多必占3~13%的藥劑量；該喜美胃錠占3~13%的藥劑量；該解痙靈占3~13%的藥劑量；該安克疼占3~13%的藥劑量；該維他命B群占3~13%的藥劑量；該維他命B1占3~13%的藥劑量；該維他命C占3~13%的藥劑量；該克多羅多克占3~13%的藥劑量；該克勞酸占3~13%的藥劑量；該補斯可伴占3~13%的藥劑量；藉由該點滴處方可活化病患肝臟及體內循環系統，使病人體內海洛英/嗎啡毒品成份迅速排除，達到阻斷毒品。
本發明之另一目的係在提供用於阻斷海洛因或嗎啡毒癮的應用，包含一急性戒斷部份及一門診部分。該急性戒斷部份包含三個階段，第一階段為急性戒斷期，分三期治療，第一期治療依據標準治療記錄單每天使用6瓶前述點滴處方，每瓶前述點滴處方再由臨床醫師依據病人臨床症狀程度添加其它對應處方注射，以活化生理解毒轉機為原則。第二期鑒於病人毒品迅速排出，毒品依賴解除，病人生理、神經傳導系統尚未恢復，臨床會產生躁動不穩，第二期治療施予病人6-9瓶前述點滴處方，並依病人躁動程度投入哈泊度及丹祈屏複方；第三期治療，以9-18瓶前述點滴處方依照標準治療程序繼續施打，以完成毒品的解除阻斷。第二階段為意識回復期，於該點滴處方內緩慢投入一2Amp的安易能，以使病人意識恢復。第三階段為身體完成恢復期，完成急性戒斷阻斷海 落英毒品傷害治療。門診部分，施予病人該點滴處方及安克疼、樂寧痛克多羅多克(Ketorolac)、維他命B12、活血素及克勞酸等，以紓解戒斷毒癮症狀及幫助循環代謝、強化生理解毒功能。藉此成功戒斷毒癮，並可透過血液檢驗，以得知病患的毒物反應狀況，達到成功阻斷吸毒行為。
第一圖所示係本發明實施例點滴處方的成份及藥劑量分配圖。
第二圖所示係本發明實施例應用流程圖。
本發明為達成上述目的，所採用之技術手段及可達致之功效，茲舉以下較佳可行實施例配合附圖進行詳細解說說明，俾能完全瞭解。
請參閱第一圖所示，本發明用於阻斷海洛因或嗎啡毒癮的點滴處方，係以活化肝臟及體內循環系統為著眼點，藉此阻斷海洛因或嗎啡毒癮。該點滴處方包含下列藥名及劑量：一活血素(學名為Cerebrolysin)，占3~13%的藥劑量，為一神經系統疾病藥物，用於治療病人神經系統疾病藥物。
一諾多必(學名為Piracetam)，占3~13%的藥劑量，為治療病人的血液系統用藥。
一喜美胃錠(學名為Cimetidine)，占3~13%的藥劑量，為治療病人的消化系統用藥。
一解痙靈(學名為Scopolamine)，占3~13%的藥劑量，為治療病人的末稍神經系統用藥/副交感神經抑制劑。
一安克疼(學名為Nefopam)，占3~13%的藥劑量，為治療病人中樞神經系統用藥。
一維他命B群(學名為Vitamin B Complex)，為一維他命劑/脂溶性維他命複方製品，占3~13%的藥劑量。
一維他命B1(學名為Thiamine(Vitamin B1))，占3~13%的藥劑量。
一維他命C(學名為Ascorbic Acid(Vitamin C))，占3~13%的藥劑量。
一克多羅多克(學名為Ketorolac)，占3~13%的藥劑量，係一非固醇類抗發炎止痛劑，用於治療病人的身體疼痛。
一克勞酸(學名為Dexrose(Glucose))，占3~13%的藥劑量，為一強肝劑，用於治療病人的藥物中毒。
一補斯可伴(學名為Hyoscine Butylbromide)，占3~13%的藥劑量，為一消化系統用藥/抗痙攣劑，用於緩解病人的消化道痙攣。
上述點滴處方以活化肝臟及體內循環系統為著眼點，對病人施打該點滴處方，使病人體內海洛英/嗎啡毒品成份迅速排除來阻斷毒癮，而且可依病人症狀不同施以不同劑量，且透過醫師及護士控管投藥時間及安全用藥劑量完成毒癮阻斷。
請參閱第二圖所示，本發明對海洛因或嗎啡毒癮之應用法係搭配前述點滴處方進行應用治療，該應用包含一急性戒斷部分及一門診部分。其中，
一.急性戒斷部分，係包含以下階段循序進行：
1.第一階段，係為期3天的急性戒斷期，依據一標準治療記錄單每天使用6瓶前述點滴處方，每瓶前述點滴處方以4小時速度依序執行投入，具有下列三個應用治療期別：
(1)第一期治療(第4-18小時)：主要係使病人體內海洛英/嗎啡毒品成份能迅速排除。投予病人第1至第5瓶前述點滴處方，由臨床醫師依據病人臨床症狀程度而添加其它輔助處方至前述點滴處方。例如：當病人臨床症狀程度為普通狀態時，於前述點滴處方內加入一2Amp的哈泊度(學名為Haloperidol)及一1Amp的丹祈屏(學名為Diazepam)；當病人臨床症狀程度為輕度狀態時，於前述點滴處方內加入一2Amp的丹祈屏(Diazepam)；當病人臨床症狀程度為全身劇烈疼痛感時，於前述點滴處方內緩慢加入一2Amp的安克疼(Nefopam)；當病人臨床症狀程度為全身中度疼痛感時，於前述點滴處方內緩慢加入一1Amp的安克疼(Nefopam)；當病人臨床症狀程度為嚴重哈欠、流眼淚並有緩解戒斷症狀功效時，於前述點滴處方內加入一1~2Amp的克多羅多克(Ketorolac)；也可加強運用維他命B12的施予，以增加解毒與迅速阻斷海洛英/嗎啡的傷害路徑、並活化肝功能與緩解神經性疼痛。也可適時補充活血素(Cerebrolysin)與克勞酸(Dexrose(Glucose))，以幫助循環代謝，強化生理解毒功能。
(2)第二期治療(第18-36小時)：該期間最重要，投入第6至第9瓶前述點滴處方。由於經第一期的治療，病人體內海洛英/嗎啡毒品成份已迅速排除，病人對毒品的依賴迅速解除。但病人因生理、神經傳導系統一時尚未恢復、無法正常運作，且病人身心潛意識因長期處在壓力狀態，致臨床躁動不穩、睡眠凌亂現像，會持續18小時無意識反復躁動發作。此時可依病人的躁動程度於該點滴處方之外，再施予病人下列輔助藥品。當病人嚴重躁動時，於該點滴處分內加入3Amp的哈泊度(Haloperidol)與2Amp的丹祈屏(Diazepam)；當病人中度躁動時，於該點滴處分內加入該2Amp的哈泊度 (Haloperidol)與2Amp的丹祈屏(Diazepam)。
(3)第三期治療(第36-72小時)，投入第9至第18瓶前述點滴處方，以陸續完成70%至95%以上的海洛英及嗎啡的急性戒斷，阻斷海洛英及嗎啡的毒品傷害。
2.第二階段，係為意識回復期1天(第72至96小時)，於該點滴處方內緩慢投入一2Amp的安易能(學名為BIPERIDEN)，俾病人經24小時意識迅速正常恢復。
3.第三階段(第96至120小時)，係為身體完成恢復期，身體基本功能進入後續生活重建階段。
據此，本發明以5天為一療程，完成急性戒斷阻斷海落英毒品傷害治療。
二.門診部分：
標準期程為6-12小時，以3瓶上述點滴處方為一療程，依據標準治療記錄單，每瓶點滴處方以2至4小時速度注射，且依病患症狀配合處方點滴緩慢投入以下處方。例如當病患具有疼痛感症狀，可於前述點滴處方中緩慢加入1~2Amp的安克疼(Nefopam)；當病患有打哈欠、流眼淚症狀，可於前述點滴處方中緩慢加入1~2Amp的克多羅多克(Ketorolac)。另外，可適時給予病人維他命B12，以增加解毒及迅速阻斷海洛英或嗎啡毒品傷害路徑，並活化肝功能與緩解神經性疼痛；可適時給予病患補充活血素(Cerebrolysin)及克勞酸(Dexrose(Glucose))，以幫助病人身體的循環代謝，並強化生理解毒功能。
是以，藉由本發明的點滴處方及應用該點滴處方的應用，以活化肝臟及體內循環系統，同時透過醫師及護士控管投藥時機及安全用藥劑量，藉此 成功阻斷病人毒癮，並可透過血液檢驗，以得知病患的毒物反應狀況，達到成功阻斷毒癮。
綜上所述，本發明確可達到預期之功能及目的，並且詳細說明能使熟於此技藝者得據以實施，然以上所舉之實施例僅用以說明本發明，舉凡所有等效結構之改變仍不脫離本發明之權利範疇。

Claims (2)

  1. 一種阻斷海洛因或嗎啡毒品中毒路徑的點滴處方，該點滴處方係包含有活血素(Cerebrolysin)、諾多必(Piracetam)、喜美胃錠(Cimetidine)、解痙靈(Scopolamine)、安克疼(Nefopam)、維他命B群(Vitamin B Complex)、維他命B1(Thiamine(Vitamin B1))、維他命C(Ascorbic Acid(Vitamin C))、克多羅多克(Ketorolac)、克勞酸(Dexrose(Glucose))及補斯可伴(Hyoscine Butylbromide)成分所組成，且每一該成分係各占3~13%的藥劑量。
  2. 一種如請求項第1項所述的點滴處方之用途，其係用於製備阻斷海洛因或嗎啡毒品中毒路徑之藥物，其中該點滴處方於病患急性戒斷時期的急性戒斷部分，係包含以下階段：第一階段的第一期，於第4-18小時投予病人第1至第5瓶前述點滴處方，每一該瓶為500ml，再依病人臨床症狀程度於前述點滴處方內加入該期輔助處方，該期輔助處方為哈泊度(Haloperidol)或丹祈屏(Diazepam)或安克疼(Nefopam)或克多羅多克(Ketorolac)藥品，以舒緩病人症狀；該輔助處方亦對病人施予維他命B12，以增加解毒與迅速阻斷海洛英/嗎啡的傷害路徑、並活化肝功能與緩解神經性疼痛；該輔助處方也對病人施予活血素(Cerebrolysin)與克勞酸(Dexrose(Glucose))，以幫助循環代謝，強化生理解毒功能；第一階段的第二期，係於第18-36小時期間，投予病患第6至第9瓶前述點滴處方，再依病人的躁動程度於該點滴處方之外，再施予病人前述輔助藥品，該輔助藥品為哈泊度(Haloperidol)與丹祈屏(Diazepam)的組成；第一階段的第三期，係於第36-72小時內，投予病患第9至第18瓶前述點滴處方，以陸續完成70%至95%以上的海洛英及嗎啡的急性戒斷，阻斷海洛英及嗎啡的毒品傷害；第二階段，於第72至96小時治療期，係為意識回復期，繼續投予病人前述點滴處方，且於該點滴處方內緩慢投入適量安易能(Biperiden)，俾病人意識迅速正常恢復；另有一門診部分，該門診部分標準期程為6-12小時，以3瓶上述點滴處方為一療程，依據標準治療記錄單，每瓶點滴處方以2至4小時速度注射，且依病患症狀配合處方點滴緩慢投入一門診輔助處方；該門診輔助處方的藥品為安克疼(Nefopam)、克多羅多克(Ketorolac)及給予病人維他命B12、活血素(Cerebrolysin)及克勞酸(Dexrose(Glucose))。
TW104140659A 2015-12-04 2015-12-04 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用 TWI646971B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TW104140659A TWI646971B (zh) 2015-12-04 2015-12-04 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
US15/000,093 US10004781B2 (en) 2015-12-04 2016-01-19 Prescription of intravenous medication for blocking heroin or morphine intoxication path and using thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW104140659A TWI646971B (zh) 2015-12-04 2015-12-04 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用

Publications (2)

Publication Number Publication Date
TW201720457A TW201720457A (zh) 2017-06-16
TWI646971B true TWI646971B (zh) 2019-01-11

Family

ID=58799479

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104140659A TWI646971B (zh) 2015-12-04 2015-12-04 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用

Country Status (2)

Country Link
US (1) US10004781B2 (zh)
TW (1) TWI646971B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009121A1 (en) * 2018-07-06 2020-01-09 En-Che Cheng Purpose for Soothing Brain Disorders of Patients from Drug Detoxification Using Biperiden HCL
EP3593804A1 (en) 2018-07-13 2020-01-15 En-Che Cheng Mecobalamin for relieving emergency drug poisoning
EP3622955A1 (en) 2018-09-17 2020-03-18 En-Che Cheng Biperiden hcl for treating brain disorders as a condequence of drug detoxification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647460A (en) * 1985-09-06 1987-03-03 Jeoungkyu Lee Composition and method for narcotics withdrawal
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
WO2007030770A2 (en) * 2005-09-09 2007-03-15 Chicago Labs, Inc. Endothelin receptors in morphine withdrawal
CN102307895A (zh) * 2008-12-04 2012-01-04 里兰斯坦福初级大学理事会 用于治疗或预防麻醉药停药症状的方法和组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Alcohol and Other drugnmwithdrawal:Practice Guidelines；2009
Heroin Add & Rel Clin Probl 2003; 5(3): 43-52
內科學誌,2009；20：139-147
內科學誌,2009；20：139-147 Alcohol and Other drugnmwithdrawal:Practice Guidelines；2009 Heroin Add & Rel Clin Probl 2003; 5(3): 43-52 *

Also Published As

Publication number Publication date
US10004781B2 (en) 2018-06-26
TW201720457A (zh) 2017-06-16
US20170157209A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
Lehmann et al. Chlorpromazine: New inhibiting agent for psychomotor excitement and manic states
Benson et al. Harnessing the power of the placebo effect and renaming it remembered wellness
JP2009528370A (ja) エピネフリン投与処方
Lehr et al. Topical anesthesia in neonates: clinical practices and practical considerations
US5789411A (en) Improvements to rapid opioid detoxification
TWI646971B (zh) 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
Nelson et al. Exacerbation of psychosis by tricyclic antidepressants in delusional depression
Martin Hypodermoclysis: renewed interest in an old technique
Marvin et al. Pain control during the intensive care phase of burn care.
CN107115359A (zh) 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
Zingade et al. Medical Emergencies in Dentistry: A Review
Avşar et al. Hypnosis and anesthesia
Alsayed Activating a Protocol for Prevention, Management and Follow up of Dermal Filler Injection Related Vascular Occlusion (A Clinical Audit)
Coughlin et al. Direct comparison of midazolam and diazepam for conscious sedation in outpatient oral surgery.
RU2150938C1 (ru) Способ лечения опийной наркомании
Yu et al. Transdermal fentanyl for management of cancer pain in elderly patients in China
Al-Sadawi et al. Pulmonary Air embolism Associated with Pneumocephalus: A Case Report
Morse Care of opiate users: detoxification
Kalko et al. Potential risk and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality
Pace Psychophysiology of pain: diagnostic and therapeutic implications
CN112353858A (zh) 一种外用安神贴
Erickson et al. Compounded analgesic therapy for disorders of movement: arthritis, neuropathic pain, and postpolio syndrome
Gao et al. Investigating the application value of propofol combined with sufentanil and dexmedetomidine in cosmetic anesthesia
Kateryna et al. Potential risks and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality
JP3927249B2 (ja) 鎮痛剤